Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index; 31 of the 69 sources its claims cite were checked for support.

Safety and efficacy concerns in Indian probiotics: Insights from whole-genome sequencing and in vitro assessment

Open access

Abstract

Acute diarrhea remains a major public health challenge in India, particularly among children, where probiotics are commonly used as adjunctive therapy. However, concerns regarding the quality, safety, and regulatory oversight of commercial probiotic formulations persist. This study evaluated 13 probiotic products marketed in India for antibiotic susceptibility, gastrointestinal survivability, and safety. A combined in vitro and genomic approach was employed, including microbial enumeration, MALDI-TOF identification, MIC testing, time-kill assays, simulated gastrointestinal survival, and whole-genome sequencing to assess strain identity, antimicrobial susceptibility, antimicrobial resistance genes (ARGs), and virulence-associated determinants. Five of the 13 products showed discrepancies between labeled and laboratory-enumerated CFU counts, and some contained contaminants such as Enterococcus faecium. Several bacterial probiotics used outdated nomenclature (e.g., “LAB” or Lactobacillus sporogenes), inconsistent with current taxonomy. Bacterial probiotics were found to be susceptible to co-prescribed antibiotics, which may compromise their therapeutic persistence. Whole-genome sequencing identified multiple antimicrobial resistance determinants, including tet(L), erm(34), blaBCL-1, catA10, and ant(4′)-Ib. Among these, tet(L), catA10, and ant(4′)-Ib showed higher predicted potential for mobilization, supported by literature and the presence of insertion sequence elements.

Overview

CoChat Summary

## TL;DR

This study evaluated 13 commercial probiotic products marketed in India using CFU enumeration, MALDI-TOF, antibiotic susceptibility testing, simulated GI survival assays, and whole-genome sequencing. It found frequent labeling and CFU discrepancies, some contamination/misidentification, and strain-specific safety differences, with S. boulardii (Econorm) performing best overall.

## Key findings

  • 5 of 13 products showed discrepancies between labeled and laboratory-enumerated CFU counts; the paper names Bifilac Sachet, Nutrolin B, Enterogermina (Vial), Sporit GG (against S. boulardii), and Ecoviva.
  • All tested strains were resistant to cefixime, with MICs ranging from 8–256 mg/L; MICs across antibiotics ranged from 0.06 to 256 mg/L.
  • In the GI simulation, Econorm (S. boulardii) had the highest survival across compartments: 8.62 ± 0.2 log CFU/mL in the stomach, 9.15 ± 0.5 in the duodenum, and 9.7 ± 0.1 in the ileum.
  • Whole-genome sequencing found multiple AMR determinants, including tet(L), erm(34), blaBCL-1, catA10, and ant(4′)-Ib; the paper says tet(L), catA10, and ant(4′)-Ib had higher predicted mobilization potential.
  • Econorm / S. boulardii showed no detected AMR genes or virulence factors and was described as the most clinically suitable product for acute diarrhea.

## Methods

  • The study assessed 13 commercially available probiotic products marketed in India, selected purposively for high prescription frequency, OTC availability, and routine clinical use.
  • It used a combined in vitro and genomic design: CFU enumeration, MALDI-TOF MS, broth microdilution MIC testing against 6 antibiotics, time-kill assays, a stepwise simulated GI digestion model, and whole-genome sequencing with bioinformatic screening for ARGs and virulence factors.
  • Analysis included strain identification and comparison of label claims vs. observed counts/taxonomy, plus genomic safety screening and interpretation of susceptibility patterns in relation to intrinsic vs. acquired resistance.

## Limitations

  • The paper states that probiotic viability was measured at a single time point per batch, without shelf-life stability or storage-time assessment.
  • It notes that the genomic context of detected AMR genes was not assessed, so mobility potential needs further investigation.
  • It also says the GI simulation was comparative and excluded control strains due to the lack of established standards.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1080/29933935.2026.2668863

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Graphical abstract
Graphical abstract CC BY · PubMed Central
Figure 1. In vitro antibiotic susceptibility profile of commercial probiotic products. The table summarizes the MICs of various antibiotics against commercially available probiotic strains. MICs were interpreted based on standard breakpoints, with red, yellow, and white indicating resistant, intermediate, and susceptible categories, respectively.
Figure 1. In vitro antibiotic susceptibility profile of commercial probiotic products. The table summarizes the MICs of various antibiotics against commercially available probiotic strains. MICs were interpreted based on standard breakpoints, with red, yellow, and white indicating resistant, intermediate, and susceptible categories, respectively.CC BY · PubMed Central
Figure 2. Time-kill assay of commercial probiotic strains against selected antibiotics. This figure illustrates the time-kill kinetics (left panels) and corresponding log₁₀ CFU/mL reduction (right panels) of various probiotic formulations upon exposure to antibiotics. Bacterial probiotics were tested at 1× MIC concentrations, while Saccharomyces boulardii was tested at Cmax levels. Each graph shows bacterial/fungal viability over time (0–24 or 48 hours), with antibiotics: cefuroxime, cefixime, amoxicillin, amoxicillin–clavulanate, ciprofloxacin, and azithromycin. The bar graphs depict log₁₀ reduction relative to the initial inoculum.
Figure 2. Time-kill assay of commercial probiotic strains against selected antibiotics. This figure illustrates the time-kill kinetics (left panels) and corresponding log₁₀ CFU/mL reduction (right panels) of various probiotic formulations upon exposure to antibiotics. Bacterial probiotics were tested at 1× MIC concentrations, while Saccharomyces boulardii was tested at Cmax levels. Each graph shows bacterial/fungal viability over time (0–24 or 48 hours), with antibiotics: cefuroxime, cefixime, amoxicillin, amoxicillin–clavulanate, ciprofloxacin, and azithromycin. The bar graphs depict log₁₀ reduction relative to the initial inoculum.CC BY · PubMed Central
Figure 3. Antimicrobial resistance genes (ARG) and virulence genes for probiotic isolates. The presence or absence of ARG is show in red line; virulence genes are denoted in yellow line and the IS elements are denoted in purple line. The color of the square box represents the copy number of the respective IS elements.
Figure 3. Antimicrobial resistance genes (ARG) and virulence genes for probiotic isolates. The presence or absence of ARG is show in red line; virulence genes are denoted in yellow line and the IS elements are denoted in purple line. The color of the square box represents the copy number of the respective IS elements.CC BY · PubMed Central

Verification

Claims the paper makes

21 Valid · 5 Not valid · 15 Not checked · 104 Own results and interpretations

73 more claims · 5 with their cited sources checked

Create a free account to see all 145 claims and to verify the 3 references still open.

See all claims — free account
  • Probably not a substantial claim. 21
  • It may state two separate claims as one. 56

Create a free account to see these claims.

Citations

Cites

Show all 45 references

Research works printed but not linked: 5

  1. Manary M, Iannotti L, Trehan I, Weisz A. Systematic review of the care of children with diarrhoea in the community-based management of severe acute malnutrition. Washington, DC: World Health Organization; 2012. Available from. https://ln.run/Ng4tj).
  2. 10.3389/fmicb.2013.00202/abstract · doi:10.3389/fmicb.2013.00202/abstract
  3. Institute LS. Clinical and laboratory standards institute. In Performance standards for antimicrobial susceptibility testing. 2024. Wayne, PA: CLSI. 34th ed.
  4. European committee on antimicrobial susceptibility testing. Breakpoint tables for interpretation of MICs and zone diameters. EUCAST. 2024;14:2024.
  5. 10.3389/fmicb.2016.01747/full · doi:10.3389/fmicb.2016.01747/full

Cited by

See all 1

Metadata

Authors
Madhumathi, I., Ramesh, V., Rathakrishnan, B., Abirami, B., Gunasekaran, K., Kumar, T. S., Jeyasankar, P., Raja, G., Selvam, K., Rajendran, S., Neeravi, A., Walia, K., & Veeraraghavan, B.
Affiliations
  • Department of Clinical Microbiology, Christian Medical College
  • Christian Medical College, Vellore (IN)
  • Division of Descriptive Research, Indian Council of Medical Research
Corresponding author
Veeraraghavan, Balaji
Venue
Gut microbes reports
Published
2026-05-14
Volume
3
Issue
1
Pages
2668863-2668863
ISSN
2993-3935 (ISSN-L)
OpenAlex
W7161181900
Cited by
0
References
45
FWCI
0.00
Type
journal article
Language
en
Open access
Locations
  • Gut Microbes Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
  • Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
Keywords
probiotics, antimicrobial resistance genes, antibiotic susceptibility, acute diarrhea, Lactobacillus, Saccharomyces boulardii, insertion sequences, tet(L), virulence factors, probiotic regulation, India

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and efficacy concerns in Indian probiotics: Insights from whole-genome sequencing and in vitro assessment. https://app.cochat.ai/papers/10.1080/29933935.2026.2668863
The paper
Madhumathi, I., Ramesh, V., Rathakrishnan, B., Abirami, B., Gunasekaran, K., Kumar, T. S., Jeyasankar, P., Raja, G., Selvam, K., Rajendran, S., Neeravi, A., Walia, K., & Veeraraghavan, B. (2026). Safety and efficacy concerns in Indian probiotics: Insights from whole-genome sequencing and in vitro assessment. Gut microbes reports. https://doi.org/10.1080/29933935.2026.2668863

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.